Finance

Lists
Outlook: 61.5% bullish·7.7% bearish
Go to analysis
TXG:NASDAQ
10X Genomics Inc
$90.04
+1.74%
(+1.54) 1D
$90.63
+0.65% (+0.59)
After hours
Closed: Sep 29, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TXG...
Open
$89.24
High
$91.99
Low
$87.29
Mkt. cap
11.73B
Avg. vol.
2.92M
Volume
3.45M
52-wk high
$91.99
52-wk low
$11.16
EPS
-$0.59
Beta
2.08
Shares outstanding
120.21M
No. of employees
1K
Open
$89.24
High
$91.99
Low
$87.29
Mkt. cap
11.73B
Avg. vol.
2.92M
Volume
3.45M
52-wk high
$91.99
52-wk low
$11.16
EPS
-$0.59
Beta
2.08
Shares outstanding
120.21M
No. of employees
1K
News stories
From web sources and news partners
Profile
10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. Wikipedia
About 10X Genomics Inc
CEOSerge Saxonov
Employees1.18K
Founded2012
HeadquartersPleasanton, California, United States
SectorHealth care
Website10xgenomics.com
Analyst ratings
Based on 16 analysts giving stock ratings to TXG in the past 3 months
Buy
Buy
7
Hold
9
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TXG in the last 3 months.
Highest
Current $90.04
$110.00 (+22.17%)
Average
$63.21 (-29.80%)
Lowest
$40.00 (-55.58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Puneet Souda
Leerink Partners
Hold
Maintained
$90.00
-0%
09/29/2026
David Westenberg
Piper Sandler
Hold
Reiterated
$80.00
-11.2%
09/28/2026
Unknown Analyst
Argus Research
Buy
Initiated
$110.00
+22.2%
09/28/2026
John Eade
Argus Research
Buy
Initiated
$110.00
+22.2%
09/25/2026
Unknown Analyst
UBS
Hold
Initiated
$68.00
-24.5%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
$68.00
-24.5%
09/09/2026
Dan Leonard
RBC Capital
Hold
Initiated
$70.00
-22.3%
09/01/2026
Unknown Analyst
Stephens
Buy
Reiterated
$65.00
-27.8%
08/12/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
$50.00
-44.5%
08/10/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$50.00
-44.5%
08/11/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Reiterated
$60.00
-33.4%
08/10/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Reiterated
$40.00
-55.6%
08/10/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
08/07/2026
Matt Larew
William Blair
Buy
Maintained
-
-
08/07/2026
Tycho Peterson
Jefferies
Buy
Reiterated
$53.00
-41.1%
08/07/2026
Patrick B Donnelly
Citi
Hold
Maintained
$50.00
-44.5%
08/07/2026
‏Brendan Digan‏
Citi
Hold
Maintained
$50.00
-44.5%
08/07/2026
Luke Sergott
Barclays
Buy
Maintained
$52.00
-42.2%
08/06/2026
Daniel Brennan
TD Cowen
Hold
Maintained
$47.00
-47.8%
07/15/2026
Justin Bowers
Deutsche Bank
Hold
Maintained
$23.00
-74.5%
05/08/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.03 / -$0.02
+258.37%beat
Revenue / Est. (USD)
151.04M / 146.62M
+3.01%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
149.00M
166.03M
150.84M
151.04M
Cost of goods sold
48.70M
52.88M
44.66M
38.54M
Cost of revenue
48.70M
52.88M
44.66M
38.54M
Research and development expenses
57.19M
55.77M
56.85M
56.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
74.66M
73.02M
66.38M
78.66M
Operating expense
131.85M
128.79M
123.22M
135.45M
Total operating expenses
180.54M
181.67M
167.89M
173.99M
Operating income
-31.54M
-15.64M
-17.05M
-22.96M
Other non operating income
538.00K
-3.04M
-72.00K
-3.49M
EBT including unusual items
-28.20M
-15.19M
-12.85M
-18.64M
EBT excluding unusual items
-26.40M
-12.39M
-12.90M
-22.04M
Income tax expense
-733.00K
1.06M
623.00K
-714.00K
Effective tax rate
2.60%
-6.97%
-4.85%
3.83%
Other operating expenses
-
-
-
-
Net income
-27.47M
-16.25M
-13.47M
-17.93M
Net profit margin
-18.44%
-9.79%
-8.93%
-11.87%
Earnings per share
-0.02
0.07
0.07
0.03
Interest and investment income
5.20M
6.89M
5.01M
4.80M
Interest expense
-
-
-
-
Net interest expenses
5.20M
6.89M
5.01M
4.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.24M
-5.58M
-7.09M
-13.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps